Results 181 to 190 of about 560,791 (351)

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

Atrial septostomy in the treatment of severe pulmonary arterial hypertension

, 2003
Frank Reichenberger
openalex   +1 more source

Surgical Treatments/Interventions for Pulmonary Arterial Hypertension [PDF]

, 2004
Ramona L. Doyle, Douglas C McCrory, Richard N. Channick, Gérald Simonneau, John V. Conte   +4 more
openalex   +1 more source

Fenfluramine's Broader Potential: A Second Notable Electroencephalogram Response in Developmental Epileptic Encephalopathy With Spike‐Wave Activation in Sleep

Annals of the Child Neurology Society, EarlyView.
Abigail Arroyo, Douglas R. Nordli III, Fernando Galan   +2 more
wiley   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Pulmonary arterial hypertension with cardiopulmonary comorbidities: is it a unique phenotype? [PDF]

BMC Pulm Med
Zhang M, Guo X, Guo W, Wang Y, Xiao Y, Han J, Li Y, Man T, Li J, Chen Y, Duan S, Zhang W, Li H, Yin A, Peng J, An C, Xie W, Gao Q, Zhang S, Zhang Y, Zhai Z, Wan J.   +21 more
europepmc   +1 more source

Pathophysiological Insights from a Case of Reversible Pulmonary Arterial Hypertension

, 2003
D Mukerjee, Edward Kingdon, Mark Vanderpump, Gerry Coghlan   +3 more
openalex   +1 more source

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides

ESC Heart Failure, Volume 12, Issue 2, Page 879-887, April 2025.
Abstract Background Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF). Aims This study aimed to characterize patients with exertional dyspnoea and normal/near‐to‐normal N‐terminal pro‐brain natriuretic peptide (NT ...
Emmanuelle Berthelot, Tarek Laouar, Antoine Beurnier, Nataliya Hrynchynshyn, Jean Christophe Eicher, Jean‐Michel Tartière, Patrick Jourdain, Olivier Lairez, Barnabas Gellen   +8 more
wiley   +1 more source

Pulmonary arterial hypertension treatment. A new era. [PDF]

Int J Cardiol Congenit Heart Dis
Mouratoglou SA, Arvanitaki A, Papadopoulos G, Souza R, Giannakoulas G.   +4 more
europepmc   +1 more source

An easily overlooked cause of pulmonary arterial hypertension-thiamine deficiency. [PDF]

Front Nutr
Zhao Q, Li M, Chen L, Qiu F.
europepmc   +1 more source